<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Enzyme Inhib Med Chem</span><span class="iso-abbrev" title="iso-abbrev">J Enzyme Inhib Med Chem</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Enzyme Inhibition and Medicinal Chemistry</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1475-6366</span><span class="issn-epub" tagx="issn" title="issn-epub">1475-6374</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Taylor &amp;amp; Francis</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7744152">7744152</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1080/14756366.2020.1858820">10.1080/14756366.2020.1858820</a></span><span class="publisher-id" title="publisher-id">1858820</span><div class="unknown" title="article-version" tag="article-version">
Version of Record</div> <div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research Article</span>: <span class="subject" title="subject">Research Paper</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
New potent steroid sulphatase inhibitors based on 6-(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives</div> <div class="alt-title" title="alt-title">
O. Ciupak et al.</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ciupak</span><span class="given-names" tagx="given-names" title="given-names">Olga</span></span><a href="#AF0001">a</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0002-3367-6491</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">DaÅ›ko</span><span class="given-names" tagx="given-names" title="given-names">Mateusz</span></span><a href="#AF0002">b</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0003-3036-8693</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Biernacki</span><span class="given-names" tagx="given-names" title="given-names">Karol</span></span><a href="#AF0001">a</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0001-5377-8228</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rachon</span><span class="given-names" tagx="given-names" title="given-names">Janusz</span></span><a href="#AF0001">a</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">MasÅ‚yk</span><span class="given-names" tagx="given-names" title="given-names">Maciej</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0001-6870-845X</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">KubiÅ"ski</span><span class="given-names" tagx="given-names" title="given-names">Konrad</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0002-7602-002X</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Martyna</span><span class="given-names" tagx="given-names" title="given-names">Aleksandra</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0002-4252-4297</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Demkowicz</span><span class="given-names" tagx="given-names" title="given-names">Sebastian</span></span><a href="#AF0001">a</a><a href="#AN0001" /></span><span class="citation_author_institution" id="AF0001">[a], <span class="institution" title="institution">Department of Organic Chemistry, Faculty of Chemistry, GdaÅ"sk University of Technology</span><span class="city" tagx="city" title="city">GdaÅ"sk</span><span class="country" tagx="country" title="country">Poland</span></span><span class="citation_author_institution" id="AF0002">[b], <span class="institution" title="institution">Department of Inorganic Chemistry, Faculty of Chemistry, GdaÅ"sk University of Technology</span><span class="city" tagx="city" title="city">GdaÅ"sk</span><span class="country" tagx="country" title="country">Poland</span></span><span class="citation_author_institution" id="AF0003">[c], <span class="institution" title="institution">Department of Molecular Biology, The John Paul II Catholic University of Lublin</span><span class="city" tagx="city" title="city">Lublin</span><span class="country" tagx="country" title="country">Poland</span></span></div> <div class="author-notes" title="author-notes"> <div class="corresp" title="corresp">
CONTACT Sebastian Demkowicz <span class="email" tagx="email" title="email">sebastian.demkowicz@pg.edu.pl</span><span class="addr-line" title="addr-line"><span class="institution" title="institution">Narutowicza</span> 11/12</span>, <span class="postal-code" tagx="postal-code" title="postal-code">80-233</span><span class="city" tagx="city" title="city">Gdansk</span>, <span class="country" tagx="country" title="country">Poland</span></div> </div><span class="pub-date-" title="pub-date-">: <span>2020-12-12</span></span><span class="pub-date-" title="pub-date-">: <span>2021</span></span><span class="volume" tagx="volume" title="volume">36</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">238</span><span class="lpage" tagx="lpage" title="lpage">247</span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">The Author(s)</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</span></span></div><a class="self-uri" href="IENZ_36_1858820.pdf" title="self-uri">IENZ_36_1858820.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>In the present work, we report a new class of potent steroid sulphatase (STS) inhibitors based on 6-(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives. Within the set of new STS inhibitors, 6-(1-(1,2,3-trifluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate <b>3L</b> demonstrated the highest activity in the enzymatic assay inhibiting the STS activity to 7.98% at 0.5â€‰ÂµM concentration. Furthermore, to verify whether the obtained STS inhibitors are able to pass through the cellular membrane effectively, cell line experiments have been carried out. We found that the lowest STS activities were measured in the presence of compound <b>3L</b> (remaining STS activity of 5.22%, 27.48% and 99.0% at 100, 10 and 1â€‰nM concentrations, respectively). The measured STS activities for <i>Irosustat</i> (used as a reference) were 5.72%, 12.93% and 16.83% in the same concentration range. Moreover, a determined IC<sub>50</sub> value of 15.97â€‰nM for <b>3L</b> showed that this compound is a very promising candidate for further preclinical investigations.</p> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Steroid sulphatase</div> <div class="kwd" title="kwd">
hormone-dependent cancer</div> <div class="kwd" title="kwd">
breast cancer</div> <div class="kwd" title="kwd">
STS inhibitors</div> <div class="kwd" title="kwd">
triazoles</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> </div> </div> <div class="body" title="body"> <div class="intro" title="intro"> <div class="title" tagx="title" title="title">
Introduction</div> <p>Cancer is the second leading cause of death worldwide. As reported by <i>International Agency for Research on Cancer</i>, there were more than 18 million new cases diagnosed and 9.5 million tumour-related deaths in 2018 worldwide<a href="#CIT0001"><sup>1</sup></a>. The most common types of cancer are lung, breast, colorectal, prostate, and stomach, which constitute almost 50% of all tumour cases. Moreover, lung, colorectal, stomach, liver, and breast cancers are responsible for nearly 50% of all deaths. <i>National Cancer Institute</i> estimates that more than 270â€‰000 (15.3%) new cases of breast cancer will be diagnosed and more than 42â€‰000 (7.0%) deaths will be reported of this disease in the United States of America in 2020<a href="#CIT0002"><sup>2</sup></a>. Approximately 95% of breast cancer cases in the primary stage are hormone-sensitive, and therefore, biological active hormones (including oestrogens and androgens) play a crucial role in the proliferation of tumours cells<a href="#CIT0003"><sup>3</sup></a>. The biosynthesis of active steroids in cancer tissues mainly depends on the following three enzymatic pathways: aromatase (responsible for the transformation of androgens into oestrogens), 17Î²-hydroxysteroid dehydrogenase (implicated in the reduction of oestrone to oestradiol) and steroid sulphatase (STS). STS acts by hydrolysing steroid sulphates (including oestrone sulphate and dehydroepiandrosterone sulphate) and therefore plays a pivotal role in human steroidogenesis process<a href="#CIT0004"><sup>4â€"7</sup></a>. Current breast cancer therapies are based on chemotherapeutics that act as selective oestrogen receptor modulators (SERMs) (e.g. <i>Tamoxifen</i>) or inhibitors of the aromatase enzyme complex (e.g. <i>Letrozole</i> or <i>Anastrozole</i>)<a href="#CIT0008"><sup>8â€"10</sup></a>. Unfortunately, both methods of treatment are unsatisfactory. The main reason for the failure of the therapy based on aromatase inhibitors is the fact that aromatase expression is significantly lower than STS<a href="#CIT0011"><sup>11</sup></a>. Furthermore, there are studies demonstrating a significant increment of STS and 17Î²-HSD1 following aromatase inhibitor therapy of ER positive postmenopausal breast carcinoma patients due to the compensatory response of breast carcinoma tissues to oestrogen depletion<a href="#CIT0012"><sup>12</sup></a>.</p> <p>Nowadays, STS has been considered as an attractive molecular target for the development of hormone-dependent cancer therapies, and therefore, the synthesis of new, efficient, selective STS inhibitors is of particular importance for modern medicinal chemistry. Recently, there has been intensive research towards finding novel STS inhibitors. Scientists have developed, both, steroidal and non-steroidal compounds containing various functional groups (e.g. sulphamate and phosphorus moieties)<a href="#CIT0013"><sup>13</sup></a>. For example, one of the most promising drug candidate based on a sulphamoylated coumarin core is <i>Irosustat</i> (also known as 667-COUMATE or STX64). <i>Irosustat</i> is in clinical trials (phase II clinical studies) and exhibits quite good results towards treating hormone-dependent breast cancer (without having <i>inÂ vivo</i> and <i>inÂ vitro</i> oestrogenic properties)<a href="#CIT0014"><sup>14â€"20</sup></a>. Although <i>Irosustat</i> showed very promising clinical effects in the treatment of hormone-dependent tumours, in relation to endometrium (where occurs high STS activity) <i>Irosustat</i> did not demonstrate activity sufficient for future commercial development<a href="#CIT0021"><sup>21</sup></a>. For this reason, the search for more effective STS inhibitors is still ongoing.</p> <p>In the present work, we described our recent research on the design, synthesis, and biological evaluation of compounds based on non-steroidal core containing triazole and naphthalene rings in their structure as new and potent STS inhibitors. The presence of the triazole ring in the structure of obtained compounds is justified by the fact that triazoles are a class of compounds showing very attractive properties and are successfully used in the design of new pharmaceuticals<a href="#CIT0022"><sup>22</sup></a>. One of the most important triazoles feature is that they do not undergo hydrolysis under acidic, basic, and redox conditions and they are stable to metabolic degradation. Moreover, these compounds are weakly acidic and weakly basic. Some properties like hydrogen bond formation, Ï€-Ï€ stacking interaction, strong dipole moments, and bioisosteric effects make triazole derivatives an attractive type of compounds in the field of medicinal chemistry. Despite the fact that 1,2,3-triazoles do not exist in the nature<a href="#CIT0023"><sup>23</sup></a> such compounds exhibit many biological activities (e.g. anticancer<a href="#CIT0024"><sup>24</sup></a><sup>,</sup><a href="#CIT0025"><sup>25</sup></a>, antimicrobial<a href="#CIT0026"><sup>26</sup></a><sup>,</sup><a href="#CIT0027"><sup>27</sup></a>, anti-infective<a href="#CIT0028"><sup>28</sup></a>).</p> </div> <div class="materials" title="materials"> <div class="title" tagx="title" title="title">
Materials and methods</div> <div class="generalmethodsandmaterials" title="sec"> <div class="title" tagx="title" title="title">
General methods and materials</div> <p>6-Bromo-2-naphthol, trimethylsilylacetylene, palladium(II) chloride, triphenylphosphine, copper(I) iodide, triethylamine, the appropriate aniline derivatives, <i>tert</i>-butyl nitrite (<i>t</i>-BuONO), azidotrimethylsilane (TMSN<sub>3</sub>), 1â€‰M solution of tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF), sodium ascorbate, copper(II) sulphate pentahydrate, chlorosulphonyl isocyanate, <i>N</i>,<i>N</i>-dimethylacetamide (<i>N</i>,<i>N</i>-DMA), and formic acid were commercially available from Sigma-Aldrich. Radiolabelled [<sup>3</sup>H] oestrone sulphate for enzyme and cellular assays was purchased from PerkinElmer. Acetonitrile (ACN) and dichloromethane (DCM) were dried and distilled using standard procedures. Melting points (uncorrected) were determined with a Stuart Scientific SMP30 apparatus. Infra-red spectra were measured on a Nicolet 8700 spectrometer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance III HD 400â€‰MHz spectrometer. Chemical shifts Î´ are reported in parts per million relative to the residual solvent peak (CDCl<sub>3</sub> = 7.26â€‰ppm for <sup>1</sup>H, 77.0â€‰ppm for <sup>13</sup>C, DMSO-d<sub>6</sub> 2.49â€‰ppm for <sup>1</sup>H, and 39.5â€‰ppm for <sup>13</sup>C). Coupling constants are given in Hertz. Mass spectra were recorded on an Agilent 6540 Accurate Mass Q-TOF LC/MS System. Elemental analysis was performed using CHNS-Carlo Erba EA-1108. Preparative thin-layer chromatography (TLC) was carried out with Polygram SIL G/UV254, silica gel (Macherey-Nagel GmbH &amp;amp; Co. KG, DÃ¼ren, Germany). Column chromatography was performed using silica gel 60 (230-400 mesh, Merck).</p> <div class="generalmethodforthesynthesisof6-((trimethylsilyl)ethynyl)naphthalen-2-ol1" title="sec"> <div class="title" tagx="title" title="title">
General method for the synthesis of 6-((trimethylsilyl)ethynyl)naphthalen-2-ol 1</div> <p>A solution of 6-bromo-2-naphthol (892â€‰mg, 4â€‰mmol), trimethylsilylacetylene (0.831â€‰ml, 6â€‰mmol), palladium(II) chloride (35.5â€‰mg, 0.20â€‰mmol), triphenylphosphine (105â€‰mg, 0.40â€‰mmol), copper(I) iodide (19â€‰mg, 0.10â€‰mmol) and triethylamine (3.94â€‰ml, 28.2â€‰mmol) in dry ACN (20â€‰ml) was refluxed under an argon atmosphere. After 3â€‰h of heating, the reaction mixture was cooled down and filtered. The filtrate was concentrated under reduced pressure and crude product was purified with column chromatography using AcOEt/hexane (1:4) as eluent to afford the desired compound <b>1</b>.</p> <p><b>6-((Trimethylsilyl)ethynyl)naphthalen-2-ol 1</b> Yield 68%; mp 92-94â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3245, 2166, 1602, 1506, 1248, 941, 836, 703; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, CDCl<sub>3</sub>) 7.96 (1H, s, Ar-H), 7.73-7.70 (1H, m, Ar-H), 7.61 (1H, d, <i>J</i>â€‰=â€‰8.5â€‰Hz, Ar-H), 7.49 (1H, dd, <i>J</i>â€‰=â€‰8.5, 1.6â€‰Hz, Ar-H), 7.14-7.11 (2H, m, Ar-H), 5.55-4.53 (1H, brs, OH) 0.31 (9H, s, CH<sub>3</sub>); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, CDCl<sub>3</sub>) 154.1, 134.2, 132.0, 129.9, 129.3, 128.3, 126.3, 118.4, 118.1, 109.6, 105.7, 93.8, 0.1; Anal. calcd for: C<sub>15</sub>H<sub>16</sub>OSi, C, 74.95; H, 6.71; O, 6.66; Si, 11.68. Found: C, 74.90; H, 6.75; O, 6.70; Si, 11.68%. HRMS (m/z) [Mâ€"H]<sup>â€"</sup> calcd 239.1155, found 239.0897.</p> </div> <div class="generalmethodforthesynthesisof6â€" title="sec"> <div class="title" tagx="title" title="title">
General method for the synthesis of 6â€"(1-phenyl-1H-1,2,3-triazol-4-yl)naphthalen-2-ol derivatives 2â€‰A-L</div> <p>To an ice-cooled solution of corresponding amine (2.63â€‰mmol) in ACN (6.1â€‰ml), <i>t</i>-BuONO (325â€‰mg, 3.16â€‰mmol) was added dropwise, followed by TMSN<sub>3</sub> (333â€‰mg, 2.89â€‰mmol). Solution was stirred at room temperature for 4â€‰h and in the next step, <b>1</b> (632â€‰mg, 2.63â€‰mmol) and 1â€‰M solution of TBAF in THF (2.89â€‰ml) were added. The reaction mixture was stirred at 0â€‰Â°C for 30â€‰min. Subsequently, CuSO<sub>4</sub> Â· 5H<sub>2</sub>O (65.7â€‰mg, 0.263â€‰mmol) and a freshly prepared aqueous solution (0.526â€‰ml) of sodium ascorbate (104â€‰mg, 0.526â€‰mmol) were added, and the obtained solution was stirred for 24â€‰h under an argon atmosphere at room temperature. Afterwards, the reaction mixture was concentrated under vacuum and the crude product was dissolved in AcOEt (30â€‰ml). Obtained solution was washed with 0.1â€‰M hydrochloric acid. After separation organic phase was dried using MgSO<sub>4</sub>, solvent was evaporated and the resulting residue was crystallised from ACN to give the desired products <b>2â€‰A-L</b>.</p> <p><b>6-(1-Phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2A</b> Yield 64%; mp (with decomposition) 228-230â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3293, 3137, 1598, 1504, 1228, 1036, 871, 683; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.87 (1H, s, OH), 9.35 (1H, s, CH), 8.39 (1H, s, Ar-H), 8.02-7.96 (3H, m, Ar-H), 7.86 (1H, d, <i>J</i>â€‰=â€‰8.8â€‰Hz, Ar-H), 7.82 (1H, d, <i>J</i>â€‰=â€‰8.7â€‰Hz, Ar-H), 7.65 (2H, t, <i>J</i>â€‰=â€‰7.9â€‰Hz, Ar-H), 7.53 (1H, t, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 7.18 (1H, d, <i>J</i>â€‰=â€‰2.3â€‰Hz, Ar-H), 7.15 (1H, dd, <i>J</i>â€‰=â€‰8.7, 2.4â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 156.2, 148.2, 137.2, 134.9, 130.4, 130.2, 129.1, 128.2, 127.3, 125.0, 124.4, 124.3, 120.4, 119.8, 119.7, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>O, C, 75.25; H, 4.56; N, 14.63; O, 5.57. Found: C, 75.31; H, 4.49; N, 14.71; O, 5.49%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 288.1132, found 288.3504.</p> <p><b>6-(1-(3-Fluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2B</b> Yield 43%; mp (with decomposition) 219-220â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3251, 3125, 2352, 1600, 1498, 1231, 1033, 870, 677; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.40 (1H, s, CH), 8.37 (1H, s, Ar-H), 7.95 (1H, dd, <i>J</i>â€‰=â€‰8.5, 1.7â€‰Hz, Ar-H), 7.93-7.80 (4H, m, Ar-H), 7.70 (1H, td, <i>J</i>â€‰=â€‰8.3, 6.5â€‰Hz, Ar-H), 7.38 (1H, tdd, <i>J</i>â€‰=â€‰8.5, 2.5, 0.7â€‰Hz, Ar-H), 7.18 (1H, d, <i>J</i>â€‰=â€‰2.1â€‰Hz, Ar-H), 7.15 (1H, dd, <i>J</i>â€‰=â€‰8.7, 2.4â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 162.9 (d, <sup>1</sup><i>J</i><sub>C-F</sub> = 245.1â€‰Hz), 156.3, 148.3, 138.4 (d, <sup>3</sup><i>J</i><sub>C-F</sub> = 10.5â€‰Hz), 134.9, 132.4 (d, <sup>3</sup><i>J</i><sub>C-F</sub> = 9.2â€‰Hz), 130.2, 128.1, 127.3, 124.8, 124.3, 119.9, 119.8, 116.3 (d, <sup>4</sup><i>J</i><sub>C-F</sub> = 3.0â€‰Hz), 115.8 (d, <sup>2</sup><i>J</i><sub>C-F</sub> = 21.0â€‰Hz), 109.3, 107.9 (d, <sup>2</sup><i>J</i><sub>C-F</sub> = 26.5â€‰Hz); Anal. calcd for: C<sub>18</sub>H<sub>12</sub>FN<sub>3</sub>O, C, 70.81; H, 3.96; F, 6.22; N, 13.76; O, 5.24. Found: C, 70.79; H, 3.99; F, 6.24; N, 13.69; O, 5.29%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 306.1038, found 306.3540.</p> <p><b>6-(1-(3-Chlorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2C</b> Yield 45%; mp (with decomposition) 229-231â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3254, 3129, 2345, 1598, 1221, 1035, 869, 679; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.43 (1H, s, CH), 8.37 (1H, s, Ar-H), 8.12 (1H, t, <i>J</i>â€‰=â€‰2.0â€‰Hz, Ar-H), 8.01 (1H, ddd, <i>J</i>â€‰=â€‰8.1, 2.0, 0.9â€‰Hz, Ar-H), 7.95 (1H, dd, <i>J</i>â€‰=â€‰8.5, 1.7â€‰Hz, Ar-H), 7.86 (1H, d, <i>J</i>â€‰=â€‰8.8â€‰Hz, Ar-H), 7.82 (1H, d, <i>J</i>â€‰=â€‰8.6â€‰Hz, Ar-H) 7.68 (1H, t, <i>J</i>â€‰=â€‰8.1â€‰Hz, Ar-H), 7.59 (1H, ddd, <i>J</i>â€‰=â€‰8.1, 1.9, 0.9â€‰Hz, Ar-H), 7.19-7.17 (1H, m, Ar-H), 7.15 (1H, dd, <i>J</i>â€‰=â€‰8.7, 2.4â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 156.3, 148.3, 138.2, 134.9, 134.7, 132.2, 130.2, 128.9, 128.1, 127.3, 124.8, 124.3, 120.2, 119.9, 119.8, 118.9, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O, C, 67.19; H, 3.76; Cl, 11.02; N, 13.06; O, 4.97. Found: C, 67.09; H, 3.84; Cl, 11.09; N, 12.99; O, 4.99%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 321.0669, found 322.3397.</p> <p><b>6-(1-(3-Bromophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2D</b> Yield 42%; mp (with decomposition) 226-228â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3271, 3130, 2922, 2350, 1583, 1489, 1034, 782; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.43 (1H, s, CH), 8.37 (1H, s, Ar-H), 8.24 (1H, s, Ar-H), 8.04 (1H, d, <i>J</i>â€‰=â€‰8.1â€‰Hz, Ar-H), 7.95 (1H, d, <i>J</i>â€‰=â€‰8.2â€‰Hz, Ar-H), 7.86 (1H, d, <i>J</i>â€‰=â€‰8.8â€‰Hz, Ar-H), 7.82 (1H, d, <i>J</i>â€‰=â€‰8.6â€‰Hz, Ar-H), 7.72 (1H, d, <i>J</i>â€‰=â€‰7.8â€‰Hz, Ar-H), 7.61 (1H, t, <i>J</i>â€‰=â€‰8.0â€‰Hz, Ar-H), 7.18 (1H, s, Ar-H), 7.15 (1H, d, <i>J</i>â€‰=â€‰8.9â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 156.3, 148.3, 138.3, 134.9, 132.4, 131.8, 130.2, 128.1, 127.3, 124.8, 124.3, 123.0, 122.9, 119.9, 119.8, 119.3, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O, C, 59.03; H, 3.30; Br, 21.82; N, 11.47; O, 4.37. Found: C, 59.11; H, 3.28; Br, 21.87; N, 11.50; O, 4.24%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 366.0237, found 366.3458.</p> <p><b>6-(1-(4-Fluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2E</b> Yield 74%; mp (with decomposition) 237-239â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3651, 3199, 3124, 2920, 2347, 1614, 1507, 1039, 802; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.33 (1H, s, CH), 8.37 (1H, s, Ar-H), 8.06-8.00 (2H, m, Ar-H), 7.96 (1H, dd, <i>J</i>â€‰=â€‰8.5, 1.5â€‰Hz, Ar-H), 7.86 (1H, d, <i>J</i>â€‰=â€‰8.8â€‰Hz, Ar-H), 7.82 (1H, d, <i>J</i>â€‰=â€‰8.6â€‰Hz, Ar-H), 7.52 (2H, t, <i>J</i>â€‰=â€‰8.8â€‰Hz, Ar-H), 7.17 (1H, s, Ar-H), 7.15 (1H, dd, <i>J</i>â€‰=â€‰8.8, 2.3â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 162.1 (d, <sup>1</sup>J<sub>C-F</sub> = 245.8â€‰Hz), 156.2, 148.2, 134.9, 133.8 (d, <sup>4</sup>J<sub>C-F</sub> = 2.8â€‰Hz), 130.1, 128.2, 127.3, 125.0, 124.4, 124.2, 122.8 (d, <sup>3</sup>J<sub>C-F</sub> = 8.8â€‰Hz), 120.0, 119.8, 117.3 (d, <sup>2</sup>J<sub>C-F</sub> = 23.3â€‰Hz), 109.2; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>FN<sub>3</sub>O, C, 70.81; H, 3.96; F, 6.22; N, 13.76; O, 5.24. Found: C, 70.75; H, 3.99; F, 6.27; N, 13.81; O, 5.18%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 306.1038, found 306.3524.</p> <p><b>6-(1-(4-Chlorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2F</b> Yield 74%; mp (with decomposition) 256-257â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3286, 3119, 2294, 1611, 1550, 1032, 831; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.38 (1H, s, CH), 8.37 (1H, s, Ar-H) 8.03 (2H, d, <i>J</i>â€‰=â€‰8.9â€‰Hz, Ar-H), 7.95 (1H, dd, <i>J</i>â€‰=â€‰8.5, 1.6â€‰Hz, Ar-H), 7.86 (1H, d, <i>J</i>â€‰=â€‰8.8â€‰Hz, Ar-H), 7.82 (1H, d, <i>J</i>â€‰=â€‰8.6â€‰Hz, Ar-H), 7.73 (2H, d, <i>J</i>â€‰=â€‰8.9â€‰Hz, Ar-H), 7.17 (1H, s, Ar-H), 7.15 (1H, dd, <i>J</i>â€‰=â€‰8.7, 2.3â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 156.3, 148.3, 136.0, 134.9, 133.4, 130.4, 130.2, 128.2, 127.3, 124.9, 124.4, 124.3, 122.1, 119.8, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O, C, 67.19; H, 3.76; Cl, 11.02; N, 13.06; O, 4.97. Found: C, 67.24; H, 3.69; Cl, 11.09; N, 13.04; O, 4.49%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 322.0742, found 322.3345.</p> <p><b>6-(1-(4-Bromophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2G</b> Yield 62%; mp (with decomposition) 254-256â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3470, 3119, 1612, 1495, 1200, 1030, 867, 810; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.38 (1H, s, CH), 8.37 (1H, s, Ar-H), 7.99-7.93 (3H, m, Ar-H), 7.88-7.80 (4H, m, Ar-H), 7.17 (1H, s, Ar-H), 7.15 (1H, dd, <i>J</i>â€‰=â€‰8.7, 2.4â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 156.3, 148.3, 136.4, 134.9, 133.3, 130.2, 128.1, 127.3, 124.9, 124.4, 124.3, 122.3, 121.7, 119.8, 119.7, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O, C, 59.03; H, 3.30; Br, 21.82; N, 11.47; O, 4.37. Found: C, 59.07; H, 3.32; Br, 21.78; N, 11.54; O, 4.29%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 366.0237, found 366.3154.</p> <p><b>6-(1-(2-Fluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2H</b> Yield 47%; mp (with decomposition) 207-208â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3177, 1614, 1511, 1048, 864, 819; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.12 (1H, d, <i>J</i>â€‰=â€‰1.9â€‰Hz, CH), 8.41 (1H, s, Ar-H), 8.02-7.91 (2H, m, Ar-H), 7.83 (2H, dd, <i>J</i>â€‰=â€‰20.5, 8.7â€‰Hz, Ar-H), 7.68-7.58 (2H, m, Ar-H), 7.54-7.45 (1H, m, Ar-H), 7.19-7.09 (2H, m, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 156.3, 154.3 (d, <sup>1</sup><i>J</i><sub>C-F</sub> = 250.8â€‰Hz), 147.8, 134.8, 131.8 (d,</p> <p><sup>2</sup><i>J</i><sub>C-F</sub> = 7.8â€‰Hz), 130.2, 128.2, 127.3, 126.5, 126.1 (d, <sup>3</sup><i>J</i><sub>C-F</sub> = 3.7â€‰Hz), 125.3 (d, <sup>2</sup><i>J</i><sub>C-F</sub> = 11.0â€‰Hz), 124.8, 124.4, 122.9 (d, <sup>3</sup><i>J</i><sub>C-F</sub> = 4.1â€‰Hz), 119.8, 117.8, 117.6, 108.9; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>FN<sub>3</sub>O, C, 70.81; H, 3.96; F, 6.22; N, 13.76; O, 5.24. Found: C, 70.78; H, 3.99; F, 6.28; N, 13.70; O, 5.25%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 306.1038, found 306.3529.</p> <p><b>6-(1-(2-Chlorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2I</b> Yield 62%; mp 104-106â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3133, 1616, 1493, 1493, 1196, 1050, 862, 804; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.08 (1H, s, CH), 8.39 (1H, s, Ar-H), 7.96 (1H, dd, <i>J</i>â€‰=â€‰8.5, 1.6â€‰Hz, Ar-H), 7.90-7.75 (4H, m, Ar-H), 7.73â€"7.59 (2H, m, Ar-H), 7.21-7.11 (2H, m, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 156.3, 147.4, 135.1, 134.9, 132.2, 131.1, 130.2, 129.0, 128.9, 128.8, 128.2, 127.3, 124.9, 124.4, 124.3, 123.7, 119.8, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O, C, 67.19; H, 3.76; Cl, 11.02; N, 13.06; O, 4.97. Found: C, 67.22; H, 3.70; Cl, 11.08; N, 13.11; O, 4.89%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 322.0742, found 322.3377.</p> <p><b>6-(1-(2-Bromophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2J</b> Yield 68%; mp 105-107â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3135, 1611, 1493, 1283, 1048, 909; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.05 (1H, s, CH), 8.39 (1H, s, Ar-H), 7.97-7.95 (2H, m, Ar-H), 7.83 (2H, dd, <i>J</i>â€‰=â€‰18.6, 8.7â€‰Hz, Ar-H), 7.77 (1H, dd, <i>J</i>â€‰=â€‰7.8, 1.6â€‰Hz), 7.67 (1H, td, <i>J</i>â€‰=â€‰7.7, 1.4â€‰Hz, Ar-H), 7.60 (1H, td, <i>J</i>â€‰=â€‰7.7, 1.4â€‰Hz, Ar-H), 7.21-7.18 (1H, m, Ar-H), 7.14 (1H, dd, <i>J</i>â€‰=â€‰8.8, 2.4â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 156.2, 147.3, 136.8, 134.9, 134.2, 132.5, 130.2, 129.5, 129.2, 128.2, 127.3, 125.0, 124.4, 124.3, 123.7, 119.8, 119.4, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O, C, 59.03; H, 3.30; Br, 21.82; N, 11.47; O, 4.37. Found: C, 59.10; H, 3.26; Br, 21.86; N, 11.36; O, 4,42%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 366.0237, found 366.3130.</p> <p><b>6-(1-(3,5-Difluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2K</b> Yield 39%; mp (with decomposition) 210-212â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3128, 1607, 1482, 1303, 1050, 911; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.43 (1H, s, CH), 8.35 (1H, s, Ar-H), 7.95-7.80 (4H, m, Ar-H), 7.46 (1H, tt, <i>J</i>â€‰=â€‰9.2, 2.2â€‰Hz, Ar-H), 7.20-7.17 (2H, m, Ar-H), 7.15 (1H, dd, <i>J</i>â€‰=â€‰8.7, 2.4â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 163.2 (dd, <sup>1</sup><i>J</i><sub>C-F</sub> = 246.9, <sup>3</sup><i>J</i><sub>C-F</sub> = 14.6â€‰Hz), 156.4, 148.4, 138.9 (t, <sup>3</sup><i>J</i><sub>C-F</sub> = 13.3â€‰Hz), 135.0, 130.2, 128.1, 127.4, 124.6, 124.4, 124.2, 120.0, 119.9, 109.3, 104.4, 104; Anal. calcd for: C<sub>18</sub>H<sub>11</sub>F<sub>2</sub>N<sub>3</sub>O, C, 66.87; H, 3.43; F, 11.75; N, 13.00; O, 4.95. Found: C, 66.90; H, 3.39; F, 11.83; N, 12.96; O, 4.92%. HRMS (m/z) [Mâ€‰+â€‰H]+ calcd 324.0943, found. 324.3554.</p> <p><b>6-(1-(2,3,4-Trifluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol 2L</b> Yield 13%; mp (with decomposition) 212-214â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3175, 1630, 1509, 1305, 1043, 912; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.14 (1H, d, <i>J</i>â€‰=â€‰1.7â€‰Hz, CH), 8.40 (1H, s, Ar-H), 7.97 (1H, dd, <i>J</i>â€‰=â€‰8.5, 1.6â€‰Hz, Ar-H), 7.89-7.77 (3H, m, Ar-H), 7.65 (1H, qd, <i>J</i>â€‰=â€‰8.5, 1.6â€‰Hz, Ar-H), 7.18-7.16 (1H, m, Ar-H), 7.14 (1H, dd, <i>J</i>â€‰=â€‰8.7, 2.3â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 156.3, 152.4-152.0 (m), 149.8-149.5 (m), 147.9, 145.8-145.4 (m), 143.2-142.9 (m), 141.6-141.2 (m), 139.2-138.7 (m), 135.0, 130.2, 128.1, 127.3, 124.5, 124.5, 124.4, 123.1 (dd, <sup>3</sup><i>J</i><sub>C-F</sub> = 8.3, <sup>4</sup><i>J</i><sub>C-F</sub> = 3.7â€‰Hz), 122.9 (d, <sup>4</sup><i>J</i><sub>C-F</sub> = 3.3â€‰Hz), 121.0 (dd, <sup>3</sup><i>J</i><sub>C-F</sub> = 8.5, <sup>4</sup><i>J</i><sub>C-F</sub> = 3.9â€‰Hz), 119.8, 113.8 (dd, <sup>2</sup><i>J</i><sub>C-F</sub> = 18.6, <sup>3</sup><i>J</i><sub>C-F</sub> = 3.8â€‰Hz), 109.; Anal. calcd for: C<sub>18</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O, C, 63.35; H, 2.95; F, 16.70; N, 12.31; O, 4.69. Found: C, 63.41; H, 2.89; F, 16.78; N, 12.39; O, 4.53%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 342.0849, found. 342.3574.</p> </div> <div class="generalmethodforthesynthesisof6-(1-phenyl-1h-1,2,3-triazol-4-yl)naphthalen-2-ylsulphamatederivatives3a-l" title="sec"> <div class="title" tagx="title" title="title">
General method for the synthesis of 6-(1-phenyl-1H-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives 3A-L</div> <p>A solution of chlorosulphonyl isocyanate (212.0â€‰mg, 1.50â€‰mmol) in anhydrous DCM (0.5â€‰ml) was prepared. In the next step, a solution of formic acid (70.9â€‰mg, 1.54â€‰mmol) and <i>N</i>,<i>N</i>-DMA (1.4â€‰mg, 0.016â€‰mmol) was added, and the reaction mixture was stirred at 40â€‰Â°C for 3.5â€‰h. Then, a solution of the corresponding derivative <b>2A-L</b> (1.00â€‰mmol) in <i>N</i>,<i>N</i>-DMA (3.4â€‰ml) was added, and the obtained solution was stirred at room temperature overnight. Subsequently, reaction mixture was poured into water (50â€‰ml). The resulting precipitate was filtered and washed with water. The crude product was recrystallized from ACN to give the desired products <b>3A-L</b>.</p> <p><b>6-(1-Phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3A</b> Yield 70%; mp (with decomposition) 210-211â€‰Â°C; Î½max (KBr)/cm<sup>âˆ’1</sup> 3119, 2915, 2358, 1595, 1352, 1168, 759, 672; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.47 (1H, s, CH), 8.59 (1H, s, Ar-H), 8.16 (1H, dd, <i>J</i>â€‰=â€‰8.6, 1.5â€‰Hz, Ar-H), 8.15-8.10 (4H, m, Ar-H, NH<sub>2</sub>), 8.00 (2H, d, <i>J</i>â€‰=â€‰7.6â€‰Hz, Ar-H), 7.88 (1H, d, <i>J</i>â€‰=â€‰2.2â€‰Hz, Ar-H), 7.67 (2H, t, <i>J</i>â€‰=â€‰7.9â€‰Hz, Ar-H), 7.54 (1H, t, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 7.51 (1H, dd, <i>J</i>â€‰=â€‰8.9, 2.4â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 148.5, 147.6, 137.1, 133.4, 131.9, 130.5, 130.4, 129.3, 129.1, 128.4, 125.0, 124.0, 122.9, 120.6, 120.5, 119.8; Anal. calcd for: C<sub>18</sub>H<sub>14</sub>N<sub>4</sub>O<sub>3</sub>S, C, 59.01; H, 3.85; N, 15.29; O, 13.10; S, 8.75. Found: C, 58.98; H, 3.88; N, 15.34; O, 13.12; S, 8.68%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 367.0860, found 367.3750.</p> <p><b>6-(1-(3-Fluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3B</b> Yield 43%; mp (with decomposition) 210-212â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3120, 2560, 1600, 1358, 1173, 782, 673; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.52 (1H, s, CH), 8.58 (1H, s, Ar-H), 8.18-8.06 (5H, m, Ar-H, NH<sub>2</sub>), 7.96-7.86 (3H, m, Ar-H), 7.72 (1H, q, <i>J</i>â€‰=â€‰7.4â€‰Hz, Ar-H), 7.50 (1H, dd, <i>J</i>â€‰=â€‰8.9, 2.2â€‰Hz, Ar-H), 7.41 (1H, td, <i>J</i>â€‰=â€‰8.7, 2.3â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 162.9 (d, <sup>1</sup><i>J</i><sub>C-F</sub> = 245.2â€‰Hz), 148.6, 147.7, 138.3, (d, <sup>3</sup><i>J</i><sub>C-F</sub> = 10.5â€‰Hz), 133.5, 132.4 (d, <sup>3</sup><i>J</i><sub>C-F</sub> = 9.1â€‰Hz), 131.9, 130.5, 129.2, 128.2, 125.0, 124.1, 122.9, 120.8, 119.8, 116.4 (d, <sup>4</sup><i>J</i><sub>C-F</sub> = 3.0â€‰Hz), 116.0 (d, <sup>2</sup><i>J</i><sub>C-F</sub> = 21.0â€‰Hz), 108.0 (d, <sup>2</sup><i>J</i><sub>C-F</sub> = 26.5â€‰Hz); Anal. calcd for: C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>3</sub>S, C, 56.24; H, 3.41; F, 4.94; N, 14.58; O, 12.49; S, 8.34. Found: C, 56.30; H, 3.45; F, 4.90; N, 14.60; O, 12.41; S, 8,43%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 385.0766, found 385.3810.</p> <p><b>6-(1-(3-Chlorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3C</b> Yield 67%; mp (with decomposition) 214-216â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3132, 2915, 2376, 1591, 1381, 1177, 784, 676; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.53 (1H, s, CH), 8.57 (1H, s, Ar-H), 8.16-8.07 (6H, m, Ar-H, NH<sub>2</sub>), 8.01 (1H, dd, <i>J</i>â€‰=â€‰7.9, 1.2â€‰Hz, Ar-H), 7.88 (1H, d, <i>J</i>â€‰=â€‰2.1â€‰Hz, Ar-H), 7.69 (1H, t, <i>J</i>â€‰=â€‰8.1â€‰Hz, Ar-H), 7.61 (1H, dd, <i>J</i>â€‰=â€‰8.0, 0.8â€‰Hz, Ar-H), 7.51 (1H, dd, <i>J</i>â€‰=â€‰8.9, 2.3â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 148.5, 147.7, 138.1, 134.7, 133.5, 132.2, 131.9, 130.5, 129.2, 129.0, 128.2, 124.9, 124.1, 122.9, 120.8, 120.3, 119.8, 119.0; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>3</sub>S, C, 53.94; H, 3.27; Cl, 8.84; N, 13.98; O, 11.97; S, 8.00. Found: C, 53.98; H, 3.29; Cl, 8.80; N, 13.94; O, 11.92; S, 8.07%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 401.0470, found 401.3646.</p> <p><b>6-(1-(3-Bromophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3D</b> Yield 34%; mp (with decomposition) 219-221â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3298, 3171, 2363, 1484, 1368, 1182, 800; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.55 (1H, s, CH), 8.58 (1H, s, Ar-H), 8.26 (1H, t, <i>J</i>â€‰=â€‰1.8â€‰Hz, Ar-H), 8.16-8.09 (5H, m, Ar-H, NH<sub>2</sub>), 8.06 (1H, dd, <i>J</i>â€‰=â€‰8.1, 1.2â€‰Hz, Ar-H), 7.88 (1H, d, <i>J</i>â€‰=â€‰2.1â€‰Hz, Ar-H), 7.75 (1H, d, <i>J</i>â€‰=â€‰8.0â€‰Hz, Ar-H), 7.63 (1H, t, <i>J</i>â€‰=â€‰8.1â€‰Hz, Ar-H), 7.50 (1H, dd, <i>J</i>â€‰=â€‰8.9, 2.3â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 148.6, 147.7, 138.2, 133.5, 132.4, 132.0, 131.9, 130.5, 129.2, 128.2, 124.9, 124.1, 123.0, 122.99, 122.90, 120.9, 119.8, 119.4; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>3</sub>S, C, 48.55; H, 2.94; Br, 17.94; N, 12.58; O, 10.78; S, 7.20. Found: C, 48.59; H, 2.96; Br, 17.90; N, 12.55; O, 10.74; S, 7.26%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 444.9965, found 445.3408.</p> <p><b>6-(1-(4-Fluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3E</b> Yield 36%; mp (with decomposition) 226-227â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3314, 3159, 1515, 1357, 1180, 838; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.44 (1H, s, CH), 8.57 (1H, s, Ar-H), 8.17-8.09 (5H, m, Ar-H, NH<sub>2</sub>), 8.07-8.01 (2H, m, Ar-H), 7.88 (1H, dd, <i>J</i>â€‰=â€‰2.0â€‰Hz, Ar-H), 7.58-7.46 (3H, m, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 162.2 (d, <sup>1</sup><i>J</i><sub>C-F</sub> = 245.9â€‰Hz), 148.5, 147.6, 133.7 (d, <sup>4</sup><i>J</i><sub>C-F</sub> = 2.8â€‰Hz), 133.4, 131.9, 130.5, 129.1, 128.4, 125.0, 124.0, 122.9 (d, <sup>3</sup><i>J</i><sub>C-F</sub> = 5.0â€‰Hz), 122.8, 120.9, 119.8, 117.3 (d, <sup>2</sup><i>J</i><sub>C-F</sub> = 23.3â€‰Hz); Anal. calcd for: C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>3</sub>S, C, 56.24; H, 3.41; F, 4.94; N, 14.58; O, 12.49; S, 8.34. Found: C, 56.27; H, 3.37; F, 4.93; N, 14.62; O, 12.53; S, 8.28%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 385.0766, found 385.3823.</p> <p><b>6-(1-(4-Chlorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3F</b> Yield 40%; mp (with decomposition) 226-229â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3372, 3269, 1502, 1352, 1173, 813; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.49 (1H, s, CH), 8.58 (1H, s, Ar-H), 8.15-8.09 (5H, m, Ar-H, NH<sub>2</sub>), 8.04 (2H, d, <i>J</i>â€‰=â€‰8.9â€‰Hz, Ar-H), 7.88 (1H, d, <i>J</i>â€‰=â€‰2.2â€‰Hz, Ar-H), 7.75 (2H, d, <i>J</i>â€‰=â€‰8.8â€‰Hz, Ar-H), 7.50 (1H, dd, <i>J</i>â€‰=â€‰8.9, 2.4â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 148.5, 147.7, 135.9, 133.52, 133.48, 131.9, 130.5, 130.4, 129.2, 128.3, 125.0, 124.1, 122.9, 122.2, 120.7, 119.7; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>3</sub>S, C, 53.94; H, 3.27; Cl, 8.84; N, 13.98; O, 11.97; S, 8.00. Found: C, 53.90; H, 3.31; Cl, 8.91; N, 14.01; O, 11.94; S, 7.93%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 401.0470, found 401.3596.</p> <p><b>6-(1-(4-Bromophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3G</b> Yield 45%; mp (with decomposition) 234-235â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3378, 3273, 3143, 1498, 1144, 710; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.50 (1H, s, CH), 8.58 (1H, s, Ar-H), 8.16-8.10 (5H, m, Ar-H, NH<sub>2</sub>), 7.97 (2H, d, <i>J</i>â€‰=â€‰8.9â€‰Hz, Ar-H), 7.89-7.86 (3H, m, Ar-H), 7.50 (1H, dd, <i>J</i>â€‰=â€‰8.9, 2.3â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 148.5, 147.7, 136.3, 133.5, 133.4, 131.9, 130.5, 129.2, 128.2, 125.0, 124.1, 122.9, 122.4, 121.9, 120.7, 119.7; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>3</sub>S, C, 48.55; H, 2.94; Br, 17.94; N, 12.58; O, 10.78; S, 7.20. Found: C, 48.59; H, 2.90; Br, 17.97; N, 12.61; O, 10.81; S, 7.12%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 445.3490, found 446.9945.</p> <p><b>6-(1-(2-Fluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3H</b> Yield 34%; mp (with decomposition) 206-207â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3398, 3277, 3148, 1502, 1111, 728; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.50 (1H, d, <i>J</i>â€‰=â€‰1.8â€‰Hz, CH), 8.61 (1H, s, Ar-H), 8.21-8.06 (5H, m, Ar-H, NH<sub>2</sub>), 7.95 (1H, td, <i>J</i>â€‰=â€‰7.9, 1.1â€‰Hz, Ar-H), 7.88 (1H, d, <i>J</i>â€‰=â€‰2.0â€‰Hz, Ar-H), 7.70-7.60 (2H, m, Ar-H), 7.55-7.45 (2H, m, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 154.5 (d, <sup>1</sup><i>J</i><sub>C-F</sub> = 250.9â€‰Hz), 148.5, 147.2, 133.5, 131.9, 130.5, 129.1, 128.2, 126.5, 126.1 (d, <sup>3</sup><i>J</i><sub>C-F</sub> = 3.8â€‰Hz), 125.3 (d, <sup>2</sup><i>J</i><sub>C-F</sub> = 10.5â€‰Hz), 125.1, 124.1, 123.8 (d, <sup>3</sup><i>J</i><sub>C-F</sub> = 4.1â€‰Hz), 122.9, 119.7, 117.8, 117.6; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>3</sub>S, C, 56.24; H, 3.41; F, 4.94; N, 14.58; O, 12.49; S, 8.34. Found: C, 56.31; H, 3.39; F, 4.90; N,14.56; O, 12.53; S, 8.31%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 385.0766, found 385.3785.</p> <p><b>6-(1-(2-Bromophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3J</b> Yield 52%; mp (with decomposition) 188-189â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3307, 3146, 3052, 1605, 1491, 1370, 929; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.19 (1H, s, CH), 8.60 (1H, s, Ar-H), 8.20-8.06 (5H, m, Ar-H, NH<sub>2</sub>), 7.98 (1H, dd, <i>J</i>â€‰=â€‰8.0, 1.3â€‰Hz, Ar-H), 7.88 (1H, d, <i>J</i>â€‰=â€‰2.2â€‰Hz, Ar-H), 7.79 (1H, dd, <i>J</i>â€‰=â€‰7.8, 1.6â€‰Hz, Ar-H), 7.68 (1H, td, <i>J</i>â€‰=â€‰7.6, 1.4â€‰Hz, Ar-H), 7.61 (1H, td, <i>J</i>â€‰=â€‰7.7, 1.7â€‰Hz, Ar-H), 7.50 (1H, dd, <i>J</i>â€‰=â€‰8.9, 2.4â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 153.7, 150.4, 137.9, 133.1, 132.2, 132.1, 131.4, 129.0, 128.9, 128.5, 126.2, 125.8, 124.7, 122.1, 120.7, 118.7, 115.5, 114.9; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>3</sub>S, C, 48.55; H, 2.94; Br, 17.94; N, 12.58; O, 10.78; S, 7.20. Found: C, 48.59, H, 2.96; Br, 17.93; N, 12.57; O, 10.72; S, 7.23%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 444.9965, found. 445.3399</p> <p><b>6-(1-(3,5-Difluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3K</b> Yield 37%; mp (with decomposition) 214-215â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3296, 3153, 3052, 1627, 1473, 1357, 916; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.55 (1H, s, CH), 8.56 (1H, s, Ar-H), 8.19-8.05 (5H, m, Ar-H, NH<sub>2</sub>), 7.88 (1H, d, <i>J</i>â€‰=â€‰2.1â€‰Hz, Ar-H), 7.85 (2H, dd, <i>J</i>â€‰=â€‰7.8, 2.0â€‰Hz, Ar-H), 7.51 (1H, dd, <i>J</i>â€‰=â€‰8.8, 2.3â€‰Hz, Ar-H), 7.46 (1H, dt, <i>J</i>â€‰=â€‰9.2, 2.2â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 163.3 (dd, <sup>1</sup><i>J</i><sub>C-F</sub> = 247.0â€‰Hz, <sup>3</sup><i>J</i><sub>C-F</sub> = 14.6â€‰Hz), 148.6, 147.7, 138.8 (t, <sup>3</sup><i>J</i><sub>C-F</sub> = 13.2â€‰Hz), 133.6, 131.9, 130.5, 129.3, 128.0, 124.9, 124.2, 122.9, 121.0, 119.8, 104.8, 104.5, 104.; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub>S, C, 53.73; H, 3.01; F, 9.44; N, 13.92; O, 11.93; S, 7.97. Found: C, 53.76; H, 3.06; F, 9.39; N, 13.87; O, 11.96; S, 7.96%. HRMS (m/z) [Mâ€‰+â€‰H]+ calcd 403.0671, found. 403.3818.</p> <p><b>6-(1-(2,3,4-Trifluorophenyl)-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3L</b> Yield 26%; mp (with decomposition) 198-200â€‰Â°C; Î½<sub>max</sub> (KBr)/cm<sup>âˆ’1</sup> 3262, 3175, 3021, 1618, 1509, 1384, 915; <sup>1</sup>H NMR Î´<sub>H</sub> (400â€‰MHz, DMSO-d<sub>6</sub>) 9.27 (1H, d, <i>J</i>â€‰=â€‰1.6â€‰Hz, CH), 8.61 (1H, s, Ar-H), 8.20-8.07 (5H, m, Ar-H, NH<sub>2</sub>), 7.91-7.83 (2H, m, Ar-H), 7.67 (1H, qd, <i>J</i>â€‰=â€‰9.8, 2.2â€‰Hz, Ar-H), 7.50 (1H, dd, <i>J</i>â€‰=â€‰8.9, 2.3â€‰Hz, Ar-H); <sup>13</sup>C NMR Î´<sub>C</sub> (101â€‰MHz, DMSO-d<sub>6</sub>) 152.4â€"152.1 (m), 149.9-149.6 (m), 148.6, 147.3, 145.9-145.6 (m), 143.3-143.0 (m), 141.7-141.2 (m), 139.2â€"138.7 (m), 133.5, 131.9, 130.5, 129.2, 127.9, 125.0, 124.3, 123.8 (d, <sup>4</sup><i>J</i><sub>C-F</sub> = 3.3â€‰Hz), 123.0 (dd, <sup>3</sup><i>J</i><sub>C-F</sub> = 8.3, <sup>4</sup><i>J</i><sub>C-F</sub> = 3.7â€‰Hz), 122.9, 121.1 (dd, <sup>3</sup><i>J</i><sub>C-F</sub> = 8.5, <sup>4</sup><i>J</i><sub>C-F</sub> = 4.0â€‰Hz), 119.7, 113.8 (dd, <sup>2</sup><i>J</i><sub>C-F</sub> = 18.6, <sup>3</sup><i>J</i><sub>C-F</sub> = 3.8â€‰Hz); Anal. calcd for: C<sub>18</sub>H<sub>11</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S, C, 51.43; H, 2.64; F, 13.56; N, 13.33; O, 11.42; S, 7.63. Found: C, 51.39; H, 2.71; F, 13.51; N, 13.29; O, 11.48; S, 7.62%. HRMS (m/z) [Mâ€‰+â€‰H]<sup>+</sup> calcd 421.0577, found. 421.3945.</p> </div> </div> <div class="moleculardocking" title="sec"> <div class="title" tagx="title" title="title">
Molecular docking</div> <div class="ligandsandmoleculartargetpreparation" title="sec"> <div class="title" tagx="title" title="title">
Ligands and molecular target preparation</div> <p>The 3â€‰D structures of the potential steroid sulphatase inhibitors (ligands) were prepared using Portable HyperChem 8.0.7 Release (Hypercube, Inc., Gainesville, FL, USA)<a href="#CIT0029"><sup>29</sup></a>. Before docking calculations, the structures of all ligands were optimised with an MMâ€‰+â€‰force field<a href="#CIT0030"><sup>30</sup></a> and the Polak-RibiÃ¨re conjugate gradient algorithm (terminating at a gradient of 0.05â€‰kcalÂ·mol<sup>âˆ’1â€‰</sup>Ã…<sup>âˆ’1</sup>). The X-ray structure of human STS was obtained from Protein Data Bank (accession code 1P49) and was prepared using standard procedure. Initially, the NAG, BOG, PO<sub>4</sub><sup>3â€"</sup> and water molecules from crystallisation were removed from the structure, and the catalytic amino acid fGly75 was converted to <i>gem</i>-diol form using the Maestro Protein Preparation Wizard module (SchrÃ¶dinger, LLC, New York, NY, USA)<a href="#CIT0031"><sup>31</sup></a>. Then, hydrogen atoms were introduced into the structure, and prepared model of the enzyme was optimised using the OPLS-AA force field<a href="#CIT0032"><sup>32</sup></a>.</p> </div> <div class="moleculardocking" title="sec"> <div class="title" tagx="title" title="title">
Molecular docking</div> <p>Docking calculations of the optimised ligands to the prepared structure of human STS were carried out with AutoDock Vina 1.1.2 software (The Molecular Graphic Laboratory, The Scripps Research Institute, La Jolla, CA, USA)<a href="#CIT0033"><sup>33</sup></a>. For all of docking studies, a grid box was centred on the CÎ² atom of amino acid 75 of the prepared STS structure, and the size of the grid box was 24â€‰Ã… Ã— 24â€‰Ã… Ã— 24â€‰Ã…. Then, the best binding modes for a particular ligand were inspected visually. Illustrations of the 3D models were prepared using VMD 1.9 (University of Illinois at Urbana-Champaign, Urbana, IL, USA)<a href="#CIT0034"><sup>34</sup></a>. Identification of the ligand-protein interactions was performed using Discovery Studio Visualiser v20. 1. 0. 19295 (BIOVIA, Dassault SystÃ©mes, San Diego, CA, USA)<a href="#CIT0035"><sup>35</sup></a>.</p> </div> </div> <div class="biologicalassays" title="sec"> <div class="title" tagx="title" title="title">
Biological assays</div> <div class="invitrostsassay" title="sec"> <div class="title" tagx="title" title="title"><i>In vitro</i> STS assay</div> <p>The STS enzyme was extracted from the human placenta, and purified using the 3-step chromatographic procedure according to the described method<a href="#CIT0036"><sup>36</sup></a>. The reaction mixtures, at a final volume of 100â€‰ÂµL, containing 20â€‰mM Tris-HCl pH = 7.4, 3â€‰nM radiolabelled [<sup>3</sup>H] oestrone sulphate, various concentrations of inhibitor and 5â€‰U of purified enzyme (1â€‰U is the amount of enzyme that hydrolyses 100â€‰nM radiolabelled [<sup>3</sup>H] oestrone sulphate in 1â€‰h at 37â€‰Â°C). The reactions were performed at 37â€‰Â°C for 30â€‰min. Afterwards, the reaction mixtures (90â€‰ÂµL) were collected from each well, and the product formed by STS-mediated hydrolysis of [<sup>3</sup>H]E1 was extracted with toluene (0.5â€‰ml). Next 0.3â€‰ml of toluene was combined with 0.3â€‰ml of scintillation liquid. STS activity was measured using the radioluminometer MicroBeta (Perkin Elmer). Assays were performed in triplicate.</p> </div> <div class="invitrocellularassayusingmcf-7breastcancercellline" title="sec"> <div class="title" tagx="title" title="title"><i>In vitro</i> cellular assay using MCF-7 breast cancer cell line</div> <p>Inhibition of STS activity in the MCF-7 breast cancer cell line was measured according to the method described by Purohit etÂ al. <a href="#CIT0037"><sup>37</sup></a>. MCF-7 cells were maintained in Dulbeccoâ€™s Modified Eagle Medium supplemented with 10% of foetal bovine serum and cultured until 80% of confluence was received. Cells were seeded in 24-well microplates (Nest Biotechnology) at a density of 1Â·10<sup>5</sup> cells/well. In order to assure an equal amount of cells in each reaction sample the number of cells was determined using a BÃ¼rker Counting Chamber. The STS activity was evaluated in living MCF-7 cells. Incubation of cells was conducted for 20â€‰h at 37â€‰Â°C in a 5% CO<sub>2</sub> humidified incubator in a serum-free medium (0.5â€‰ml) with radiolabelled oestrone sulphate [<sup>3</sup>H]E1S (4Â·105â€‰cpm, 3â€‰nM) with or without an inhibitor. After incubation, a medium containing STS-mediated reaction product was collected (0.45â€‰ml) from each well and the product was isolated from the mixture by extraction with toluene (4â€‰ml). The STS activity expressed as the level of product radioactivity was measured using the Radioluminometer MicroBeta (Perkin Elmer). Cellular assay was carried out in triplicate. IC<sub>50</sub> values were calculated using GraphPad Prism software.</p> </div> </div> </div> <div class="results" title="results"> <div class="title" tagx="title" title="title">
Results and discussion</div> <div class="moleculardocking" title="sec"> <div class="title" tagx="title" title="title">
Molecular docking</div> <p>Initially, to verify that the 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives are able to effectively bind to the STS active site, molecular docking studies were performed. The X-ray structure of STS was retrieved from the Protein Data Bank (Protein Data Bank accession code 1P49) and properly prepared for docking calculations. The docking procedure of the optimised ligands was performed using AutoDock Vina 1.1.2 software (Molecular Graphics Laboratory, The Scripps Research Institute, LaJolla, CA). The calculated results for the proposed structures of the inhibitors <b>3A-L</b> were at a satisfactory, comparable level in the range of âˆ’6.0 to âˆ’8.3â€‰kcalÂ·mol<sup>âˆ’1</sup> (the measurement error for the AutoDock Vina software is 2.85â€‰kcalÂ·mol<sup>âˆ’1</sup>) (<a href="#t0001">Table 1</a>) and lower than the free energy of binding value of the reference inhibitor <i>Irosustat</i> (â€"5.4â€‰kcalÂ·mol<sup>âˆ’1</sup>). The most favourable binding energy was determined for compound <b>3L</b> (â€"8.3â€‰kcalÂ·mol<sup>âˆ’1</sup>) suggesting that this compound could theoretically create the most stable inhibitor-enzyme complex in the STS active site, leading to effective inhibition.</p> <div class="table-wrap_UNKNOWN" id="t0001" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1.</span> <p>Free energies of binding calculated for compounds <b>3â€‰A-L</b> and <i>Irosustat</i>.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th colspan="7" align="left"><span class="inline-graphic" title="inline-graphic" /><hr /> </th> </tr> <tr> <th align="left">No.</th> <th align="center">R<sub>1</sub></th> <th align="center">R<sub>2</sub></th> <th align="center">R<sub>3</sub></th> <th align="center">R<sub>4</sub></th> <th align="center">R<sub>5</sub></th> <th align="center">Free energies of binding [kcalÂ·mol<sup>-1</sup>]</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>3A</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"7.4</td> </tr> <tr> <td align="left"><b>3B</b></td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"7.7</td> </tr> <tr> <td align="left"><b>3C</b></td> <td align="center">H</td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"6.4</td> </tr> <tr> <td align="left"><b>3D</b></td> <td align="center">H</td> <td align="center">Br</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"6.3</td> </tr> <tr> <td align="left"><b>3E</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"7.6</td> </tr> <tr> <td align="left"><b>3F</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"7.6</td> </tr> <tr> <td align="left"><b>3G</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">Br</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"6.0</td> </tr> <tr> <td align="left"><b>3H</b></td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"8.0</td> </tr> <tr> <td align="left"><b>3I</b></td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"7.9</td> </tr> <tr> <td align="left"><b>3J</b></td> <td align="center">Br</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"8.0</td> </tr> <tr> <td align="left"><b>3K</b></td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">â€"7.9</td> </tr> <tr> <td align="left"><b>3L</b></td> <td align="center">F</td> <td align="center">F</td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="center">â€"8.3</td> </tr> <tr> <td align="left"><i>Irosustat</i></td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"5.4</td> </tr> </tbody> </table> </div> <p>In order to analyse the ligand-protein interactions that could be responsible for the stabilisation of the inhibitor-enzyme complexes, studies using BIOVIA, Dassault SystÃ©mes, Discovery Studio Visualiser software have been carried out. Our research has shown that the newly designed potential STS inhibitors based on 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives were able to create the complexes with the STS protein stabilised by a number of interactions including Ï€-alkyl, alkyl, Ï€-sulphur, conventional hydrogen bond, carbon hydrogen bond, Ï€-cation, or Ï€-sigma (listed in <a href="#t0002">Table 2</a>). The largest number of interactions was detected for compounds <b>3E</b>, <b>3F</b>, <b>3G</b>. However, apart from the above-mentioned numerous interactions, an extremely important aspect (influencing the inhibitory properties of STS inhibitors based on aryl-sulphamate derivatives) is their ability to undergo the nucleophilic substitution reactions on the sulphur atom. Although the mechanism of action is not confirmed and remains a topic of discussion, a sulphamate functional group (sulphate mimic) might be transferred to fGly75 residue leading to irreversible inhibition of the STS enzyme<a href="#CIT0021"><sup>21</sup></a>. The visualisation of the putative binding mode for compounds <b>3L</b> using VMD 1.9 (University of Illinois at Urbana-Champaign, Urbana, IL, USA) is shown in <a href="#F0001">Figure 1</a>. The sulphamate functional group, which is directly responsible for the inactivation of the enzyme, is located in the catalytic region of STS close to the fGly75 residue coordinated to Ca<sup>2+</sup> and stabilised by Ï€-sulphur interaction with His290 (the distance between the sulphur atom of <b>3L</b> and OH group of fGly75 is 2.90â€‰Ã…). For this reason, we suppose that the compound <b>3L</b> (despite a smaller number of electrostatic interactions indicated by the docking program) may prove to be the most effective due to the very close distance of the sulphamate group to fGly75 residue. Furthermore, the tetracyclic core of compound <b>3L</b> is well accommodated in the STS active site and is surrounded by some hydrophobic amino acid residues (e.g. Leu103, Leu167, Phe178, Phe182, Phe237, Val486, Phe488, and Phe553). Interestingly, the fluorine atoms of compound <b>3L</b> are within a short distance to the nitrogen atoms of the Arg98 residue (4.12 and 4.29â€‰Ã…), indicating the possibility of electrostatic interactions (undetected by the Discovery Studio Visualiser). On the other hand, the presence of the fluorine atoms may be crucial for its potentially increased ability to undergo the enzymatic reaction. Highly electronegative fluorine atoms may reduce the pKa value of the molecule, making it a good leaving group in the nucleophilic substitution reaction on the sulphur atom. In addition, the molecular modelling studies indicated (<a href="#F0001">Figure 1</a>) that the triazole ring of compound <b>3L</b> is located close to the Thr484 residue, suggesting an additional interaction including hydrogen bond between OH group of Thr484 and ring-nitrogen atom (5.81â€‰Ã…). These detected interaction points may be responsible for an enhancement of inhibitory potency by stabilisation of the potential STS inhibitor in the enzymeâ€™s active site.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1.</span></a></div>   <p>Docked binding modes and distance to fGly75, Arg98 and Thr484 for compound <b>3â€‰L</b> (CPK coloured) and <i>Irosustat</i> (pink).</p>   </div> <div class="table-wrap_UNKNOWN" id="t0002" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 2.</span> <p>The ligand-protein interactions (and distances [Ã…]) identified using BIOVIA, Dassault SystÃ©mes, Discovery Studio Visualiser.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th colspan="8" align="left"><span class="inline-graphic" title="inline-graphic" /><hr /> </th> </tr> <tr> <th align="left">No.</th> <th align="center">Ï€â€"Alkyl</th> <th align="center">Alkyl</th> <th align="center">Ï€â€"Sulphur</th> <th align="center">Conventional Hydrogen Bond</th> <th align="center">Carbon Hydrogen Bond</th> <th align="center">Ï€â€"Cation</th> <th align="center">Ï€â€"Sigma</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>3A</b></td> <td align="left">LEU103 (6.16, 6.50); VAL486 (5.86); VAL101 (4.93, 6.33); VAL177 (6.12)</td> <td align="center">â€"</td> <td align="left">HIS290 (5.76); HIS136 (6.93)</td> <td align="left">THR165 (4.11)</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"</td> </tr> <tr> <td align="left"><b>3B</b></td> <td align="left">LEU103 (6.13, 6.47); VAL486 (5.50, 6.07), VAL101 (5.31), VAL177 (5.50, 5.57)</td> <td align="center">â€"</td> <td align="left">HIS290 (6.00)</td> <td align="left">FGLY75 (4.18), LYS368 (5.02)</td> <td align="left">HIS136 (5.74, 7.12)</td> <td align="center">â€"</td> <td align="center">â€"</td> </tr> <tr> <td align="left"><b>3C</b></td> <td align="left">LEU103 (5.91); VAL486 (6.16); VAL101 (5.43); VAL177 (5.43, 5.63)</td> <td align="left">ARG98 (2.99), TRP550 (6.97)</td> <td align="left">HIS290 (5.75);<br /><br />HIS136 (7.13)</td> <td align="center">â€"</td> <td align="left">HIS136 (6.04)</td> <td align="left">ARG98 (4.40)</td> <td align="center">â€"</td> </tr> <tr> <td align="left"><b>3D</b></td> <td align="left">LEU103 (5.51); VAL101 (4.85); VAL177 (4.85, 5.55)</td> <td align="left">ARG98 (3.08); TRP550 (6.86)</td> <td align="left">HIS290 (5.79);<br /><br />HIS136 (7.11)</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="left">ARG98 (4.83)</td> <td align="left">Â </td> </tr> <tr> <td align="left"><b>3E</b></td> <td align="left">ARG98 (4.57, 6.35);<br /><br />VAL177 (6.26); VAL486 (5.36), VAL101 (6.07)</td> <td align="center">â€"</td> <td align="left">HIS290 (5.43); HIS136 (6.78)</td> <td align="left">LYS134 (6.65); ASP36 (4.96); GLN343 (5.61)</td> <td align="left">THR165 (5.41)</td> <td align="center">â€"</td> <td align="left">VAL101 (4.93)</td> </tr> <tr> <td align="left"><b>3F</b></td> <td align="left">ARG98 (4.74); VAL177<br /><br />(6.49); VAL101 (5.81), VAL486 (5.37)</td> <td align="center">â€"</td> <td align="left">HIS290 (5.29); HIS136 (6.73)</td> <td align="left">LYS134 (5.37), THR165 (4.20)</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="left">VAL101 (4.78)</td> </tr> <tr> <td align="left"><b>3G</b></td> <td align="left">ARG98 (4.95); VAL177 (5.24, 5.96), VAL486 (5.30), VAL101 (6.42)</td> <td align="left">LEU185 (5.88)</td> <td align="left">HIS290 (4.87,<br /><br />5.32); HIS136<br /><br />(6.72)</td> <td align="left">LYS368 (5.58), LYS134 (6.45), GLN343 (5.45), ASP36 (4.95), ASP35 (4.95)</td> <td align="left">HIS136 (5.58)</td> <td align="center">â€"</td> <td align="left">VAL101 (5.29)</td> </tr> <tr> <td align="left"><b>3H</b></td> <td align="left">LEU103 (6.23, 6.49); VAL486 (6.21); VAL101 (5.38); VAL177 (5.49, 5.69)</td> <td align="center">â€"</td> <td align="left">HIS290 (5.96); HIS136 (7.09)</td> <td align="left">FGLY75 (4.25, 5.14); LYS368<br /><br />(3.69)</td> <td align="left">HIS136 (5.74)</td> <td align="center">â€"</td> <td align="center">â€"</td> </tr> <tr> <td align="left"><b>3I</b></td> <td align="left">PHE178 (4.53); LEU103 (6.27, 6.56); VAL177 (5.46, 5.79); VAL486 (5.96), VAL101 (5.42)</td> <td align="center">â€"</td> <td align="left">HIS290 (6.01); HIS136 (7.08)</td> <td align="left">LYS368 (5.15)</td> <td align="left">HIS136 (5.73)</td> <td align="center">â€"</td> <td align="center">â€"</td> </tr> <tr> <td align="left"><b>3J</b></td> <td align="left">PHE178 (4.48); LEU103<br /><br />(6.15, 6.43), VAL177 (5.50, 5.67); VAL486 (6.08); <br /><br />VAL101 (5.34)</td> <td align="center">â€"</td> <td align="left">HIS290 (5.92); <br /><br />HIS136 (7.05)</td> <td align="left">LYS368 (5.18); FGLY75 (3.04, <br /><br />4.27)</td> <td align="left">HIS136 (5.69)</td> <td align="left">ARG98 (4.90)</td> <td align="center">â€"</td> </tr> <tr> <td align="left"><b>3K</b></td> <td align="left">LEU103 (6.18, 6.60); <br /><br />VAL486 (5.95); VAL101<br /><br />(5.40); VAL177 (5.26, 5.68)</td> <td align="center">â€"</td> <td align="left">HIS290 (5.91); <br /><br />HIS136 (7.05)</td> <td align="left">ARG98 (5.14)</td> <td align="left">HIS136 (5.67)</td> <td align="center">â€"</td> <td align="center">â€"</td> </tr> <tr> <td align="left"><b>3L</b></td> <td align="left">VAL177 (4.32); VAL486 (5.09, 5.61); LEU74 (6.53)</td> <td align="center">â€"</td> <td align="left">HIS290 (5.57)</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="left">VAL101 (5.12)</td> </tr> <tr> <td align="left"><i>Irosustat</i></td> <td align="left">VAL177 (6.51); VAL486<br /><br />(4.87, 5.08) VAL101 (5.09)</td> <td align="center">â€"</td> <td align="left">HIS290 (5.73); <br /><br />HIS136 (6.84)</td> <td align="left">LYS368 (5.49); <br /><br />FGLY75 (3.04)</td> <td align="left">HIS136 (6.03)</td> <td align="center">â€"</td> <td align="left">VAL486 (4.67)</td> </tr> </tbody> </table> </div> </div> <div class="chemistry" title="sec"> <div class="title" tagx="title" title="title">
Chemistry</div> <p>The newly designed compounds <b>3A-L</b> based on 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives were synthesised according to the route shown in (<a href="#SCH001">Scheme 1</a>). In the first step, we synthesised 6-((trimethylsilyl)ethynyl)naphthalen-2-ol <b>1</b> by the Sonogashira coupling reaction between 6-bromo-2-naphthol and trimethylsilylacetylene. Next step included the preparation of 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol derivatives <b>2â€‰A-L</b> by a 1,3-dipolar cycloaddition reaction. In this case the corresponding azide derivatives (obtained from commercially available anilines by the reaction with <i>t</i>-BuONO and TMSN<sub>3</sub>) were treated with <b>1</b> in the presence of CuSO<sub>4</sub> Â· 5H<sub>2</sub>O (0.1 equiv.), sodium ascorbate (0.2 equiv.), and TBAF. Finally, 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-ol derivatives <b>2â€‰A-L</b> were sulphamoylated using sulphamoyl chloride previously generated in the reaction of chlorosulphonyl isocyanate and formic acid in the presence of a catalytic amount of <i>N</i>,<i>N</i>-DMA. After standard isolation, the desired derivatives <b>3A-L</b> were obtained.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 1.</span></a></div>   <p>Synthesis of 6-((trimethylsilyl)ethynyl)naphthalen-2-ol <b>1</b> and 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives (R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> = H, F, Cl, or Br) <b>3â€‰A-L</b>.</p>   </div> </div> <div class="biologicalevaluation" title="sec"> <div class="title" tagx="title" title="title">
Biological evaluation</div> <div class="enzymaticassayusingthestsenzymeisolatedfromthehumanplacenta" title="sec"> <div class="title" tagx="title" title="title">
Enzymatic assay using the STS enzyme isolated from the human placenta</div> <p>In the next step of our investigation, the synthesised new STS inhibitors based on 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives <b>3A-L</b> were tested in the enzymatic assay (at 0.5â€‰ÂµM of inhibitor concentration) in order to verify their theoretical potential to inhibit of the STS activity. Screening tests were performed using the STS enzyme isolated from the human placenta and purified by a 3-step chromatography procedure. After purification, the obtained fraction was used directly as the enzyme source. In this activity assay, a radiolabelled [<sup>3</sup>H] oestrone sulphate has been used as a substrate to provide higher selectivity and more reliable results. The summarised results of the enzymatic assay for newly synthesised 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives <b>3A-L</b> are presented in <a href="#t0003">Table 3</a>. The received data showed that all compounds effectively inhibited the activity of the steroid sulphatase to a level from 7.98 to 27.17%. In the course of the research, we found that the highest inhibitory activity was exhibited by the compound <b>3L</b> containing three fluorine atoms in its structure (remaining STS activity of 7.98%). This result was in agreement with the data from the molecular modelling studies. It was observed that the substitution of the terminal aromatic ring with a less halogen atoms resulted in a decrease in the activity of the tested compounds towards STS. This observation may confirm our assumptions that the higher number of electronegative heteroatoms may reduce the pKa value of the inhibitor cores, making them more susceptible to nucleophilic substitution reaction on the sulphur atom. The obtained results may also suggest that the position of the halogen substitution in the above-mentioned aryl ring may be crucial for the potency of evaluated compounds. As it turns out, the presence of halogen atoms at the R<sub>1</sub> and R<sub>2</sub> positions may have the greatest influence on the increase of inhibitory potency. On the other hand, the type of substituent is slightly less significant.</p> <div class="table-wrap_UNKNOWN" id="t0003" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 3.</span> <p>The STS inhibitory effect of the newly synthesised compounds <b>3â€‰A-L</b> at 0.5â€‰<i>Âµ</i>M inhibitor concentration.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th colspan="7" align="left"><span class="inline-graphic" title="inline-graphic" /><hr /> </th> </tr> <tr> <th align="left">No.</th> <th align="center">R<sub>1</sub></th> <th align="center">R<sub>2</sub></th> <th align="center">R<sub>3</sub></th> <th align="center">R<sub>4</sub></th> <th align="center">R<sub>5</sub></th> <th align="center">Remaining STS activity [%]</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>3A</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">24.50â€‰Â±â€‰1.36</td> </tr> <tr> <td align="left"><b>3B</b></td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">17.40â€‰Â±â€‰0.87</td> </tr> <tr> <td align="left"><b>3C</b></td> <td align="center">H</td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">9.66â€‰Â±â€‰0.48</td> </tr> <tr> <td align="left"><b>3D</b></td> <td align="center">H</td> <td align="center">Br</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">9.62â€‰Â±â€‰0.48</td> </tr> <tr> <td align="left"><b>3E</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">23.75â€‰Â±â€‰1.22</td> </tr> <tr> <td align="left"><b>3F</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">18.71â€‰Â±â€‰0.94</td> </tr> <tr> <td align="left"><b>3G</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">Br</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">23.07â€‰Â±â€‰1.15</td> </tr> <tr> <td align="left"><b>3H</b></td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">27.17â€‰Â±â€‰1.36</td> </tr> <tr> <td align="left"><b>3I</b></td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">16.93â€‰Â±â€‰0.83</td> </tr> <tr> <td align="left"><b>3J</b></td> <td align="center">Br</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">15.93â€‰Â±â€‰0.80</td> </tr> <tr> <td align="left"><b>3K</b></td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="char" char="Â±">14.03â€‰Â±â€‰0.70</td> </tr> <tr> <td align="left"><b>3L</b></td> <td align="center">F</td> <td align="center">F</td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">7.98â€‰Â±â€‰0.40</td> </tr> </tbody> </table> </div> </div> <div class="evaluationofstsinhibitioninthemcf-7cellline" title="sec"> <div class="title" tagx="title" title="title">
Evaluation of STS inhibition in the MCF-7 cell line</div> <p>The next step of the biological evaluation was to verify whether the obtained new STS inhibitors based on 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamates <b>3A-L</b> are able to inhibit STS activity in the MCF-7 cancer cell line. In the course of our study, we determined the level of STS inhibition in the MCF-7 cells after incubation in the presence of inhibitors at 100, 10, and 1â€‰nM concentrations. The summarised results are presented in <a href="#t0004">Table 4</a>. In the course of our research, we found that in the presence of inhibitor at 100â€‰nM concentration, the lowest STS activities were measured for derivatives <b>3K</b> (5.43% of STS activity) and <b>3L</b> (5.29% of STS activity) substituted at R<sub>1</sub>, R<sub>2</sub> or R<sub>3</sub> position with fluorine atoms. These results were comparable with those obtained for the reference compound â€" <i>Irosustat</i> (remaining STS activity of 5.72%). In the next step, six of the most promising derivatives <b>3G-L</b> were selected and tested at an inhibitor concentration of 10â€‰nM. Among these compounds, the highest STS inhibitory activities were observed for the derivatives <b>3I</b>, <b>3K</b>, and <b>3L</b> (remaining STS activity of 42.09%, 42.01% and 27.48%, respectively). As the research showed, the tested compounds showed slightly weaker activity in comparison with <i>Irosustat</i> (remaining STS activity of 12.93% at an inhibitor concentration of 10â€‰nM). In order to further verify the potential of the new selected compounds, the STS activity was measured in the presence of <b>3I</b>, <b>3K</b>, and <b>3L</b> at the inhibitor concentration of 1â€‰nM. For these compounds, an IC<sub>50</sub> parameter was determined as well. The studies showed that the tested compounds based on 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamates <b>3I</b>, <b>3K</b>, and <b>3L</b> found to be very potent STS inhibitors characterised by low IC<sub>50</sub> values of 30.14, 17.02, 15.97â€‰nM, respectively (IC<sub>50</sub> parameter determined for <i>Irosustat</i> was 1.14â€‰nM). The obtained results indicated that 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamates may be very promising in further <i>inÂ vivo</i> studies. Overall, among all the newly prepared compounds, the highest activity was shown by those with fluorine atoms in their structures. We assume that their effectiveness may be influenced by the possibility of electrostatic interactions between fluorine atoms and the Arg98 residue in the STS active site (as suggested in molecular modelling studies) as well as a higher susceptibility of these structures to nucleophilic substitution reaction on the sulphur atom. Moreover, the presence of C-F bonds in the structure of biologically active compounds often affects a number of favourable properties, including metabolic stability, leading to higher therapeutic effectiveness.</p> <div class="table-wrap_UNKNOWN" id="t0004" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 4.</span> <p>Remaining STS activity in MCF-7 cells after incubation with compounds <b>3â€‰A-L</b> and <i>Irosustat</i> at 100, 10 and 1â€‰nM inhibitor concentrations.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th colspan="10" align="left"><span class="inline-graphic" title="inline-graphic" /><hr /> </th> </tr> <tr> <th rowspan="2" align="left">No.</th> <th rowspan="2" align="center">R<sub>1</sub></th> <th rowspan="2" align="center">R<sub>2</sub></th> <th rowspan="2" align="center">R<sub>3</sub></th> <th rowspan="2" align="center">R<sub>4</sub></th> <th rowspan="2" align="center">R<sub>5</sub></th> <th colspan="3" align="center">Remaining STS activity [%] <hr /> </th> <th align="center">Â </th> </tr> <tr> <th align="center">100 [nM]</th> <th align="center">10 [nM]</th> <th align="center">1 [nM]</th> <th align="center">IC<sub>50</sub> [nM]</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>3A</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">15.52â€‰Â±â€‰0.78</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> </tr> <tr> <td align="left"><b>3B</b></td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">12.22â€‰Â±â€‰0.61</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> </tr> <tr> <td align="left"><b>3C</b></td> <td align="center">H</td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">22.05â€‰Â±â€‰1.10</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> </tr> <tr> <td align="left"><b>3D</b></td> <td align="center">H</td> <td align="center">Br</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">20.59â€‰Â±â€‰1.03</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> </tr> <tr> <td align="left"><b>3E</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">11.32â€‰Â±â€‰0.57</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> </tr> <tr> <td align="left"><b>3F</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">13.25â€‰Â±â€‰0.66</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> </tr> <tr> <td align="left"><b>3G</b></td> <td align="center">H</td> <td align="center">H</td> <td align="center">Br</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">8.68â€‰Â±â€‰0.43</td> <td align="char" char="Â±">59.86â€‰Â±â€‰2.99</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> </tr> <tr> <td align="left"><b>3H</b></td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">8.80â€‰Â±â€‰0.44</td> <td align="char" char="Â±">55.84â€‰Â±â€‰2.79</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> </tr> <tr> <td align="left"><b>3I</b></td> <td align="center">Cl</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">7.44â€‰Â±â€‰0.37</td> <td align="char" char="Â±">42.09â€‰Â±â€‰2.10</td> <td align="char" char="Â±">84.32â€‰Â±â€‰4.22</td> <td align="char" char="Â±">30.14â€‰Â±â€‰1.51</td> </tr> <tr> <td align="left"><b>3J</b></td> <td align="center">Br</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">7.30â€‰Â±â€‰0.37</td> <td align="char" char="Â±">59.45â€‰Â±â€‰2.97</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">â€"</td> </tr> <tr> <td align="left"><b>3K</b></td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="center">F</td> <td align="center">H</td> <td align="char" char="Â±">5.43â€‰Â±â€‰0.27</td> <td align="char" char="Â±">42.01â€‰Â±â€‰2.10</td> <td align="char" char="Â±">79.30â€‰Â±â€‰3.96</td> <td align="char" char="Â±">17.02â€‰Â±â€‰0.85</td> </tr> <tr> <td align="left"><b>3L</b></td> <td align="center">F</td> <td align="center">F</td> <td align="center">F</td> <td align="center">H</td> <td align="center">H</td> <td align="char" char="Â±">5.29â€‰Â±â€‰0.26</td> <td align="char" char="Â±">27.48â€‰Â±â€‰1.37</td> <td align="char" char="Â±">99.00â€‰Â±â€‰4.95</td> <td align="char" char="Â±"><b>15.97â€‰</b>Â±<b>â€‰0.80</b></td> </tr> <tr> <td align="left"><i>Irosustat</i></td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="center">â€"</td> <td align="char" char="Â±">5.72â€‰Â±â€‰0.29</td> <td align="char" char="Â±">12.93â€‰Â±â€‰0.65</td> <td align="char" char="Â±">16.83â€‰Â±â€‰0.84</td> <td align="char" char="Â±">1.14â€‰Â±â€‰0.06</td> </tr> </tbody> </table> </div> </div> </div> </div> <div class="conclusions" title="conclusions"> <div class="title" tagx="title" title="title">
Conclusions</div> <p>In the present work, we described our research on molecular modelling, synthesis, and biological evaluation of 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives <b>3A-L</b> as new very potent STS inhibitors. Screening enzymatic assay, performed using the STS enzyme isolated from the human placenta indicated that all of the newly synthesised inhibitors <b>3A-L</b> were able to effectively inhibit the action of STS. Among them, the highest inhibitory activity was exhibited by compound <b>3L</b> containing three fluorine atoms in its structure (remaining STS activity of 7.98%). In the course of the cell line experiment, we observed the highest inhibition of STS in the presence of 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamates <b>3I</b>, <b>3K</b>, and <b>3L</b> characterised by low IC<sub>50</sub> values of 30.14, 17.02, 15.97â€‰nM, respectively (IC<sub>50</sub> value determined for <i>Irosustat</i> was 1.14â€‰nM). The presented results showed that 6â€"(1-phenyl-1<i>H</i>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives may be very promising anticancer agents and their therapeutic potential should be confirmed in further <i>inÂ vivo</i> studies. Furthermore, the data of enzymatic and cell line experiments suggested that the possibility of creating electrostatic interactions between the fluorine atoms of compounds and the Arg98 residue in the active site of STS as well as a higher susceptibility to nucleophilic substitution reaction on the sulphur atom could be critical for their inhibitory effects.</p> </div> </div> <div class="back" title="back"> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Disclosure statement</div> <p>The authors report no conflict of interest.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CIT0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: IARC: CANCER FACT SHEETS [Internet]</span></span> Lyon (France): International Agency for Research on Cancer. Available from: <a href="https://gco.iarc.fr/today/factsheets-cancers">https://gco.iarc.fr/today/factsheets-cancers</a> [last accessed 10 May 2020].</span></li> <li tag="ref"><a name="CIT0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: NCI [Internet]</span></span> Maryland (U.S.): National Cancer Institiute. Available from: <a href="https://seer.cancer.gov/statfacts/html/breast.html">https://seer.cancer.gov/statfacts/html/breast.html</a> [last accessed on 10 May 2020].</span></li> <li tag="ref"><a name="CIT0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pasqualini</span><span class="given-names" tagx="given-names" title="given-names">JR.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The selective estrogen enzyme modulators in breast cancer: a review</span>. <span class="source" tagx="source" title="source">Biochim Biophys Acta Rev</span><span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">1654</span>:<span class="fpage" tagx="fpage" title="fpage">123</span>â€"<span class="lpage" tagx="lpage" title="lpage">43</span>.</span></li> <li tag="ref"><a name="CIT0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Purohit</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Woo</span><span class="given-names" tagx="given-names" title="given-names">LWL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Potter</span><span class="given-names" tagx="given-names" title="given-names">BVL.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism</span>. <span class="source" tagx="source" title="source">Mol Cell Endocrinol</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">340</span>:<span class="fpage" tagx="fpage" title="fpage">154</span>â€"<span class="lpage" tagx="lpage" title="lpage">60</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21693170">21693170</a></span></span></li> <li tag="ref"><a name="CIT0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shah</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Singh</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Singh</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Sulfatase inhibitors for recidivist breast cancer treatment: a chemical review</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">114</span>:<span class="fpage" tagx="fpage" title="fpage">170</span>â€"<span class="lpage" tagx="lpage" title="lpage">90</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26974384">26974384</a></span></span></li> <li tag="ref"><a name="CIT0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reed</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Purohit</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Woo</span><span class="given-names" tagx="given-names" title="given-names">LWL</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Steroid sulfatase: molecular biology, regulation, and inhibition</span>. <span class="source" tagx="source" title="source">Endocr Rev</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">26</span>:<span class="fpage" tagx="fpage" title="fpage">171</span>â€"<span class="lpage" tagx="lpage" title="lpage">202</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15561802">15561802</a></span></span></li> <li tag="ref"><a name="CIT0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zaraei</span><span class="given-names" tagx="given-names" title="given-names">S-O</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abduelkarem</span><span class="given-names" tagx="given-names" title="given-names">AR</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Anbar</span><span class="given-names" tagx="given-names" title="given-names">HS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Sulfamates in drug design and discovery: pre-clinical and clinical investigations</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">179</span>:<span class="fpage" tagx="fpage" title="fpage">257</span>â€"<span class="lpage" tagx="lpage" title="lpage">71</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31255926">31255926</a></span></span></li> <li tag="ref"><a name="CIT0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ring</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dowsett</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Mechanisms of tamoxifen resistance</span>. <span class="source" tagx="source" title="source">Endocr Relat Cancer</span><span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">11</span>:<span class="fpage" tagx="fpage" title="fpage">643</span>â€"<span class="lpage" tagx="lpage" title="lpage">58</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15613444">15613444</a></span></span></li> <li tag="ref"><a name="CIT0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Foster</span><span class="given-names" tagx="given-names" title="given-names">PA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chander</span><span class="given-names" tagx="given-names" title="given-names">SK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Newman</span><span class="given-names" tagx="given-names" title="given-names">SP</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor</span>. <span class="source" tagx="source" title="source">Clin Cancer Res</span><span class="year" tagx="year" title="year">2008</span>;<span class="volume" tagx="volume" title="volume">14</span>:<span class="fpage" tagx="fpage" title="fpage">6469</span>â€"<span class="lpage" tagx="lpage" title="lpage">77</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18927286">18927286</a></span></span></li> <li tag="ref"><a name="CIT0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dixon</span><span class="given-names" tagx="given-names" title="given-names">JM.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Endocrine resistance in breast cancer</span>. <span class="source" tagx="source" title="source">New J Sci</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">2014</span>:<span class="fpage" tagx="fpage" title="fpage">1</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.</span></li> <li tag="ref"><a name="CIT0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Foster</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reed</span><span class="given-names" tagx="given-names" title="given-names">PA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Purohit</span><span class="given-names" tagx="given-names" title="given-names">MJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Recent developments of steroid sulfatase inhibitors as anti-cancer agents</span>. <span class="source" tagx="source" title="source">Anticancer Agents Med Chem</span><span class="year" tagx="year" title="year">2008</span>;<span class="volume" tagx="volume" title="volume">8</span>:<span class="fpage" tagx="fpage" title="fpage">732</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18855575">18855575</a></span></span></li> <li tag="ref"><a name="CIT0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chanplakorn</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chanplakorn</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Suzuki</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Increased estrogen sulfatase (STS) and 17Î²-hydroxysteroid dehydrogenase type 1(17Î²-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients</span>. <span class="source" tagx="source" title="source">Breast Cancer Res Treat</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">120</span>:<span class="fpage" tagx="fpage" title="fpage">639</span>â€"<span class="lpage" tagx="lpage" title="lpage">48</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20151319">20151319</a></span></span></li> <li tag="ref"><a name="CIT0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">DaÅ›ko</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Demkowicz</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Biernacki</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Recent progress in the development of steroid sulphatase inhibitors - examples of the novel and most promising compounds from the last decade</span>. <span class="source" tagx="source" title="source">J Enzyme Inhib Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">35</span>:<span class="fpage" tagx="fpage" title="fpage">1163</span>â€"<span class="lpage" tagx="lpage" title="lpage">84</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32363947">32363947</a></span></span></li> <li tag="ref"><a name="CIT0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Malini</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Purohit</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ganeshapillai</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates</span>. <span class="source" tagx="source" title="source">J Steroid Biochem Mol Biol</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">75</span>:<span class="fpage" tagx="fpage" title="fpage">253</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11282279">11282279</a></span></span></li> <li tag="ref"><a name="CIT0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Woo</span><span class="given-names" tagx="given-names" title="given-names">LWL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Purohit</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Malini</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates</span>. <span class="source" tagx="source" title="source">Chem Biol</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">7</span>:<span class="fpage" tagx="fpage" title="fpage">773</span>â€"<span class="lpage" tagx="lpage" title="lpage">91</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11033081">11033081</a></span></span></li> <li tag="ref"><a name="CIT0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stanway</span><span class="given-names" tagx="given-names" title="given-names">SJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Purohit</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Woo</span><span class="given-names" tagx="given-names" title="given-names">LWL</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor</span>. <span class="source" tagx="source" title="source">Clin Cancer Res</span><span class="year" tagx="year" title="year">2006</span>;<span class="volume" tagx="volume" title="volume">12</span>:<span class="fpage" tagx="fpage" title="fpage">1585</span>â€"<span class="lpage" tagx="lpage" title="lpage">92</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16533785">16533785</a></span></span></li> <li tag="ref"><a name="CIT0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Palmieri</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Januszewski</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stanway</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Coombes</span><span class="given-names" tagx="given-names" title="given-names">RC.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer</span>. <span class="source" tagx="source" title="source">Expert Rev Anticancer Ther</span><span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">11</span>:<span class="fpage" tagx="fpage" title="fpage">179</span>â€"<span class="lpage" tagx="lpage" title="lpage">83</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21342037">21342037</a></span></span></li> <li tag="ref"><a name="CIT0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Palmieri</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stein</span><span class="given-names" tagx="given-names" title="given-names">RC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">X</span></span></span>, <span class="person-group'"><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients</span>. <span class="source" tagx="source" title="source">Breast Cancer Res Treat</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">165</span>:<span class="fpage" tagx="fpage" title="fpage">343</span>â€"<span class="lpage" tagx="lpage" title="lpage">53</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28612226">28612226</a></span></span></li> <li tag="ref"><a name="CIT0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Palmieri</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stein</span><span class="given-names" tagx="given-names" title="given-names">RC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) â€" trial results</span>. <span class="source" tagx="source" title="source">J Clin Oncol</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">34</span>:<span class="fpage" tagx="fpage" title="fpage">549</span>.</span></li> <li tag="ref"><a name="CIT0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Palmieri</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Szydlo</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Miller</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer</span>. <span class="source" tagx="source" title="source">Breast Cancer Res Treat</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">166</span>:<span class="fpage" tagx="fpage" title="fpage">527</span>â€"<span class="lpage" tagx="lpage" title="lpage">39</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28795252">28795252</a></span></span></li> <li tag="ref"><a name="CIT0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Potter</span><span class="given-names" tagx="given-names" title="given-names">BVL.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Sulfation pathways: steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects</span>. <span class="source" tagx="source" title="source">J Mol Endocrinol</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">61</span>:<span class="fpage" tagx="fpage" title="fpage">T233</span>â€"<span class="lpage" tagx="lpage" title="lpage">T252</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29618488">29618488</a></span></span></li> <li tag="ref"><a name="CIT0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">DaÅ›ko</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Demkowicz</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rachon</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">New potent STS inhibitors based on fluorinated 4-(1-phenyl-1<i>H</i>-[1,2,3]triazol-4-yl)-phenyl sulfamates</span>. <span class="source" tagx="source" title="source">J Asian Nat Prod Res</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">1037</span>â€"<span class="lpage" tagx="lpage" title="lpage">44</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31773975">31773975</a></span></span></li> <li tag="ref"><a name="CIT0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bozorov</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aisa</span><span class="given-names" tagx="given-names" title="given-names">HA.</span></span></span><span class="mixed-article-title" title="mixed-article-title">1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: a recent overview</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">27</span>:<span class="fpage" tagx="fpage" title="fpage">3511</span>â€"<span class="lpage" tagx="lpage" title="lpage">31</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31300317">31300317</a></span></span></li> <li tag="ref"><a name="CIT0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kommidi</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guo</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nurili</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title"><sup>18</sup>F-positron emitting/trimethine cyanine-fluorescent contrast for image-guided prostate cancer management</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">61</span>:<span class="fpage" tagx="fpage" title="fpage">4256</span>â€"<span class="lpage" tagx="lpage" title="lpage">62</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29676909">29676909</a></span></span></li> <li tag="ref"><a name="CIT0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huang</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Han</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Radiosynthesis and biological evaluation of <sup>18</sup>F-labeled 4-anilinoquinazoline derivative (<sup>18</sup>F-FEA-Erlotinib) as a potential EGFR PET agent</span>. <span class="source" tagx="source" title="source">Bioorganic Med Chem Lett</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">28</span>:<span class="fpage" tagx="fpage" title="fpage">1143</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.</span></li> <li tag="ref"><a name="CIT0026" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhou</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stapleton</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Haider</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Healy</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Boronic acid inhibitors of the class A Î²-lactamase KPC-2</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">26</span>:<span class="fpage" tagx="fpage" title="fpage">2921</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29784271">29784271</a></span></span></li> <li tag="ref"><a name="CIT0027" /><span class="label" tagx="label" title="label">27</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lopes</span><span class="given-names" tagx="given-names" title="given-names">SMM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Novais</span><span class="given-names" tagx="given-names" title="given-names">JS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Costa</span><span class="given-names" tagx="given-names" title="given-names">DCS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Hetero-Diels-Alder reactions of novel 3-triazolyl-nitrosoalkenes as an approach to functionalized 1,2,3-triazoles with antibacterial profile</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">143</span>:<span class="fpage" tagx="fpage" title="fpage">1010</span>â€"<span class="lpage" tagx="lpage" title="lpage">20</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29232578">29232578</a></span></span></li> <li tag="ref"><a name="CIT0028" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Batra</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rajendran</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Agarwal</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and antimalarial evaluation of [1,2,3]-Triazole-Tethered Sulfonamide-Berberine Hybrids</span>. <span class="source" tagx="source" title="source">ChemistrySelect</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">3</span>:<span class="fpage" tagx="fpage" title="fpage">9790</span>â€"<span class="lpage" tagx="lpage" title="lpage">3</span>.</span></li> <li tag="ref"><a name="CIT0029" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: HyperChem(TM) Professional 7.51, Hypercube, Inc., 1115 NW 4th Street</span></span>, Gainesville, Florida, USA.Â Available from: <a href="http://www.hyper.com">www.hyper.com</a></span></li> <li tag="ref"><a name="CIT0030" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hocquet</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">LanggÃ¥rd</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">An evaluation of the MMâ€‰+â€‰force field</span>. <span class="source" tagx="source" title="source">J Mol Model</span><span class="year" tagx="year" title="year">1998</span>;<span class="volume" tagx="volume" title="volume">4</span>:<span class="fpage" tagx="fpage" title="fpage">94</span>â€"<span class="lpage" tagx="lpage" title="lpage">122</span>.</span></li> <li tag="ref"><a name="CIT0031" /><span class="label" tagx="label" title="label">31</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: SchrÃ¶dinger Release 2020-3: Maestro</span></span>, <span class="person-group'"><span class="collab'">collab: SchrÃ¶dinger</span></span>, LLC, New York, NY, <span class="year" tagx="year" title="year">2020</span>.</span></li> <li tag="ref"><a name="CIT0032" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kaminski</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Duffy</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Matsui</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jorgensen</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Free energies of hydration and pure liquid properties of hydrocarbons from the OPLS All-Atom Model</span>. <span class="source" tagx="source" title="source">J Phys Chem</span><span class="year" tagx="year" title="year">1994</span>;<span class="volume" tagx="volume" title="volume">98</span>:<span class="fpage" tagx="fpage" title="fpage">13077</span>â€"<span class="lpage" tagx="lpage" title="lpage">82</span>.</span></li> <li tag="ref"><a name="CIT0033" /><span class="label" tagx="label" title="label">33</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Trott</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Olson</span><span class="given-names" tagx="given-names" title="given-names">AJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Autodock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span>. <span class="source" tagx="source" title="source">J Comput Chem</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">31</span>:<span class="fpage" tagx="fpage" title="fpage">455</span>â€"<span class="lpage" tagx="lpage" title="lpage">61</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19499576">19499576</a></span></span></li> <li tag="ref"><a name="CIT0034" /><span class="label" tagx="label" title="label">34</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Humphrey</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dalke</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schulten</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">VMD: visual molecular dynamics</span>. <span class="source" tagx="source" title="source">J Mol Graph</span><span class="year" tagx="year" title="year">1996</span>;<span class="volume" tagx="volume" title="volume">14</span>:<span class="fpage" tagx="fpage" title="fpage">33</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8744570">8744570</a></span></span></li> <li tag="ref"><a name="CIT0035" /><span class="label" tagx="label" title="label">35</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: BIOVIA</span></span>, Dassault SystÃ¨mes. Discovery Studio Visualizer, v20. 1. 0. 19295. San Diego: Dassault SystÃ¨mes; <span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="CIT0036" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hernandez-Guzman</span><span class="given-names" tagx="given-names" title="given-names">FG</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Higashiyama</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Osawa</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ghosh</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Purification, characterization and crystallization of human placental estrone/dehydroepiandrosterone sulfatase, a membrane-bound enzyme of the endoplasmic reticulum</span>. <span class="source" tagx="source" title="source">J Steroid Biochem Mol Biol</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">78</span>:<span class="fpage" tagx="fpage" title="fpage">441</span>â€"<span class="lpage" tagx="lpage" title="lpage">50</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11738554">11738554</a></span></span></li> <li tag="ref"><a name="CIT0037" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Purohit</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Williams</span><span class="given-names" tagx="given-names" title="given-names">GJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Howarth</span><span class="given-names" tagx="given-names" title="given-names">NM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate</span>. <span class="source" tagx="source" title="source">Biochemistry</span><span class="year" tagx="year" title="year">1995</span>;<span class="volume" tagx="volume" title="volume">34</span>:<span class="fpage" tagx="fpage" title="fpage">11508</span>â€"<span class="lpage" tagx="lpage" title="lpage">14</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7547880">7547880</a></span></span></li> </ul> </div> </div>  </body></html>